SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Leifras Co., Ltd. Engages in sport training, event and alliance & club activity support and healthcare activities. It provides services related to the organization and operations of sports schools and sports events for children and it also operate a robust social business sector, dispatching sports coaches to meet various community needs. The company was founded by Kiyotaka Ito on August 28, 2001 and is headquartered in Tokyo, Japan.

Leifras Co Ltd - ADR

Leifras Co Ltd

Leifras Co Ltd ($LFS) is trending due to significant price movement, sparking excitement and FOMO among traders. Community discussions revolve around the potential for a short squeeze, with some comparing it to previous high-flying stocks and anticipating further gains, while others caution about a potential pump and dump.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending as the price of Bitcoin, a key asset for the company, experiences volatility, sparking debate about MicroStrategy's leveraged exposure and future prospects. Community discussions range from short-squeeze potential and bottom-fishing opportunities to concerns about debt and possible liquidation scenarios. Traders are actively monitoring technical levels and options activity to gauge near-term price movements.

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Olema Pharmaceuticals Inc

Olema Pharmaceuticals is trending due to optimism surrounding its breast cancer drug pipeline, spurred by positive data from a Roche trial of a similar treatment; some believe this de-risks OLMA's own SERD development. The community is discussing potential buyout scenarios and key resistance levels, while others caution about a possible offering and question the stock's valuation. Price target upgrades are contributing to the bullish sentiment.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors brace for earnings, with high expectations and worries about stretched valuations creating market anxiety. Community discussions revolve around the sustainability of the AI boom and the potential impact of earnings on the broader market, especially as recent large deals highlight circular investments. Traders are closely watching for signs of an AI bubble and how NVDA's report could influence market direction.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals is trending due to FDA approval of their drug Redemplo for reducing triglycerides, leading to a temporary halt in trading. The community is excited about the approval, seeing it as a validation of Arrowhead's pipeline and a potential catalyst for future growth. Some are speculating on potential price targets and takeover offers, while others are focused on the potential market share Redemplo could capture.

Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF

MSTY is trending as investors discuss its correlation to Bitcoin's price movements and MicroStrategy's performance, with some expressing concern over NAV erosion despite weekly dividend payouts. Community members are actively debating strategies such as reinvesting dividends, hedging with inverse ETFs like WNTR, and managing risk amid market volatility, as well as analyzing the potential for future gains if Bitcoin and MSTR rebound. There is also discussion around how YieldMax funds go down over time, and debate on whether to cut losses and move on, or to keep accumulating.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending as investors discuss a potential breakout and the company's upcoming presentation at the Inflammatory Skin Disease Summit. Community members are optimistic about the stock's potential, citing strong institutional ownership and a potentially positive FDA meeting in December. Some are speculating about a gamma squeeze, with bullish sentiment fueled by best-in-class data and a tight float.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is trending as investors analyze the company's growth potential and recent earnings, with community members pointing to bullish chart patterns and oversold conditions. Some are debating the impact of potential buybacks and significant contracts, particularly a $1.4 billion AI data center project. Others express concern over short selling activity and the stock's volatile price movements within the broader tech sector.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending due to a mix of factors, including a recent Rothschild downgrade citing concerns over AI profitability and value leakage, along with news of a $10 billion investment in a Portuguese AI data hub. Despite some negative sentiment and analysts debating AI's potential bubble, the community is actively discussing dip-buying opportunities and Microsoft's long-term strategic partnerships, particularly with Anthropic and NVIDIA.

Klarna Group Plc operates as an investment holding company. It provides an e-commerce payment solutions for merchants and shoppers. The firm connect an array of different financial services and commerce organizations, from PSPs, traditional banks, card networks and open banking providers, to commerce enablers, technology partners, in-store payments providers and shipping and return logistics providers. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending as investors discuss the company's Q3 performance and recent strategic moves, including a $6.5 billion loan sale and partnerships with Google and Qatar Airways. Community sentiment is mixed, with some bullish on the company's growth potential and AI integration, while others express concerns about profitability and market conditions. Discussions also involve Klarna's competition within the Buy Now Pay Later (BNPL) sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$APP $GOOG $NVDA $META $MU 

Following strong third-quarter results, several analysts have recently upgraded Applovin&#39;s price target, with prominent examples including Scotiabank raising its target to $750, Benchmark increasing its target to $700, and Royal Bank of Canada lifting its target to $750. These upgrades reflect positive Q3 performance and strong management guidance. 
Recent upgrades
Scotiabank: Raised target from $575 to $750.
Benchmark: Increased target from $640 to $700.
Royal Bank of Canada (RBC): Raised target from $700 to $750.
UBS: Lifted target to $840.
Piper Sandler: Moved target to $800. 
Key reasons for upgrades
Strong Q3 results: The company reported a 68% year-over-year increase in revenue and a 79% year-over-year rise in adjusted EBITDA.
Positive management commentary: Analysts were encouraged by management&#39;s outlook, which cited drivers like expanding ad supply, a diversified content portfolio, and improved user retention.
Positive forward guidance: Piper Sandler specifically noted strong forward guidance from the company, projecting significant quarter-over-quarter growth. 
Analyst consensus
The average price target from multiple analyst sources is around $658–$749, with a consensus rating of &quot;Strong Buy&quot; or &quot;Moderate Buy&quot;.
Analyst targets range from a low of $200–$435 to a high of $860.

StockTwits for iOS

Applovin Corp

Alphabet Inc - Ordinary Shares - Class C

Nvidia is trending as investors brace for the chipmaker's earnings report, which is seen as a critical test for the AI-powered market rally. Community discussions range from anticipating a potential 'sell the news' event regardless of the earnings outcome, to debating the sustainability of AI-driven growth and the company's valuation. Some traders are also pointing to insider selling and broader market concerns as reasons to be cautious.

Meta Platforms Inc

Micron Technology Inc

 

Following strong third-quarter results, several analysts have recently upgraded Applovin's price target, with prominent examples including Scotiabank raising its target to $750, Benchmark increasing its target to $700, and Royal Bank of Canada lifting its target to $750. These upgrades reflect positive Q3 performance and strong management guidance. 
Recent upgrades
Scotiabank: Raised target from $575 to $750.
Benchmark: Increased target from $640 to $700.
Royal Bank of Canada (RBC): Raised target from $700 to $750.
UBS: Lifted target to $840.
Piper Sandler: Moved target to $800. 
Key reasons for upgrades
Strong Q3 results: The company reported a 68% year-over-year increase in revenue and a 79% year-over-year rise in adjusted EBITDA.
Positive management commentary: Analysts were encouraged by management's outlook, which cited drivers like expanding ad supply, a diversified content portfolio, and improved user retention.
Positive forward guidance: Piper Sandler specifically noted strong forward guidance from the company, projecting significant quarter-over-quarter growth. 
Analyst consensus
The average price target from multiple analyst sources is around $658–$749, with a consensus rating of "Strong Buy" or "Moderate Buy".
Analyst targets range from a low of $200–$435 to a high of $860.